Athersys Inc (ATHXQ)

[KMBJN]

No, I haven't heard anything about this investigator initiated Phase I trial of Multistem in liver transplant - just what ClinicalTrials.gov shows - still recruiting 12 subjects, after 18 months estimating enrollment complete next April (4 months).

I did last week see an interesting poster about neuro-immune response after seizures in epilepsy: immune cells leave the spleen after a seizure, and those mice with repeated seizures have activated T4 and T8 cells in their brains. I thought that sounded awfully similar to the stroke story of neuroinflammation and injury (with MultiStem preventing the spleen from shrinking after stroke and providing benefit in stroke recovery in animal models), and was wondering if MultiStem might have another potential indication.

I was responding in the previous post to Expediter's criticism of "finding out they started a trial without a PR" when in fact the trial of MultiStem in AMI has apparently not begun yet (but is scheduled to start this month). NBS had some interesting results recently with a nice dose response to their stem cells in AMI, but the market seemed to have only read the headline results and Adam F.'s description of the events.